Circulating Tumor DNA Directs Precision Management for Ovarian Cancer

Oncology Times - OncTimes Talk

Drug resistance can be delayed and treatment outcomes predicted in patients with ovarian cancer with the help of relatively low-cost molecular precision management techniques using liquid biopsies. These are being developed by a team at the University of California in Los Angeles (UCLA) led by Jian Yu Rao, MD, Vice Chair of Diagnostic Technology Innovation at UCLA, where he is also Chief of Cytopathology and Director of International Telepathology.

At the 2024 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) held in Xiamen, China, Rao gave Oncology Times reporter Peter Goodwin details of the molecular methods he had just outlined to the conference.